Shigeki Umemura

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

Medicine, Oncology, Pharmacology +14

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis

Shigeki Umemura, Sachiyo Mimaki, Hideki Makinoshima et al. · Journal of Thoracic Oncology · 2014 · 219 citations · Full text

Medicine, Genetics, Oncology +17

Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung

Tomohiro Miyoshi, Shigeki Umemura, Yuki Matsumura et al. · Clinical Cancer Research · 2016 · 193 citations · Full text

Medicine, Genetics, Oncology +17

Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma

Hideki Makinoshima, Masahiro Takita, Koichi Saruwatari et al. · Journal of Biological Chemistry · 2015 · 188 citations · Full text

Life Sciences, Biochemistry, Oncology +17